Abeona Therapeutics Inc. (ABEO) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Abeona Therapeutics Inc. (ABEO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

5.09

-0.52 (-9.27%)

At close: Jan 14, 2025, 3:59 PM

5.11

0.39%

After-hours Jan 14, 2025, 05:26 PM EST

undefined% (undefined)

Bid	5.09
Market Cap	221.27M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.05
PE Ratio (ttm)	-2.48
Forward PE	n/a
Analyst	Buy

Ask	5.98
Volume	624,470
Avg. Volume (20D)	253,440
Open	5.66
Previous Close	5.61
Day's Range	5.05 - 5.66
52-Week Range	3.05 - 9.01
Beta	undefined

About ABEO

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease;...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 19, 1980

Employees 84

Stock Exchange NASDAQ

Ticker Symbol ABEO

Website https://www.abeonatherapeutics.com

Analyst Forecast

According to 3 analyst ratings, the average rating for ABEO stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 253.63% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Abeona Therapeutics Inc. is scheduled to release its earnings on Mar 17, 2025, before market opens.
Analysts project revenue of $83.33K, reflecting a n/a YoY growth and earnings per share of -0.34, making a -46.88% decrease YoY.

Why Price Moved

5 months ago · Source

+11.99%

Abeona Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

8 months ago · Source

+12.14%

Abeona Therapeutics shares are trading higher. The company reported Q1 financial results.

News

3 months ago · seekingalpha.com

Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy

Abeona Therapeutics' Pz-cel, a gene-corrected cell therapy for RDEB, is expected to resubmit its BLA in 2H2024, targeting FDA approval by mid-2025. ABEO's AIM platform uses AAV vectors for targeted ge...